6.
Liu S, Nambiar Veetil N, Li Q, Kucherenko M, Knosalla C, Kuebler W
. Pulmonary hypertension: Linking inflammation and pulmonary arterial stiffening. Front Immunol. 2022; 13:959209.
PMC: 9579293.
DOI: 10.3389/fimmu.2022.959209.
View
7.
Sade L, Ozin B, Ulus T, Acikel S, Pirat B, Bilgi M
. Right ventricular contractile reserve in mitral stenosis: implications on hemodynamic burden and clinical outcome. Int J Cardiol. 2008; 135(2):193-201.
DOI: 10.1016/j.ijcard.2008.03.050.
View
8.
Galie N, Brundage B, Ghofrani H, Oudiz R, Simonneau G, Safdar Z
. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009; 119(22):2894-903.
DOI: 10.1161/CIRCULATIONAHA.108.839274.
View
9.
Oudiz R, Galie N, Olschewski H, Torres F, Frost A, Ghofrani H
. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54(21):1971-81.
DOI: 10.1016/j.jacc.2009.07.033.
View
10.
Michelfelder E, Vermilion R, Ludomirsky A, Beekman R, Lloyd T
. Comparison of simultaneous Doppler- and catheter-derived right ventricular dP/dt in hypoplastic left heart syndrome. Am J Cardiol. 1996; 77(2):212-4.
DOI: 10.1016/s0002-9149(96)90604-9.
View
11.
Mathai S, Puhan M, Lam D, Wise R
. The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012; 186(5):428-33.
PMC: 3443803.
DOI: 10.1164/rccm.201203-0480OC.
View
12.
Chirinos J, Akers S, Vierendeels J, Segers P
. A Unified Mechanism for the Water Hammer Pulse and Pulsus Bisferiens in Severe Aortic Regurgitation: Insights from Wave Intensity Analysis. Artery Res. 2018; 21:9-12.
PMC: 5863934.
DOI: 10.1016/j.artres.2017.12.002.
View
13.
Ameloot K, Palmers P, Vande Bruaene A, Gerits A, Budts W, Voigt J
. Clinical value of echocardiographic Doppler-derived right ventricular dp/dt in patients with pulmonary arterial hypertension. Eur Heart J Cardiovasc Imaging. 2014; 15(12):1411-9.
DOI: 10.1093/ehjci/jeu134.
View
14.
Simonneau G, Gatzoulis M, Adatia I, Celermajer D, Denton C, Ghofrani A
. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013; 62(25 Suppl):D34-41.
DOI: 10.1016/j.jacc.2013.10.029.
View
15.
Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V
. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006; 173(9):1023-30.
DOI: 10.1164/rccm.200510-1668OC.
View
16.
Semen K, Yelisyeyeva O, Jarocka-Karpowicz I, Kaminskyy D, Solovey L, Skrzydlewska E
. Sildenafil reduces signs of oxidative stress in pulmonary arterial hypertension: Evaluation by fatty acid composition, level of hydroxynonenal and heart rate variability. Redox Biol. 2015; 7:48-57.
PMC: 4683386.
DOI: 10.1016/j.redox.2015.11.009.
View
17.
Masutani S, Iwamoto Y, Ishido H, Senzaki H
. Relationship of maximum rate of pressure rise between aorta and left ventricle in pediatric patients. Implication for ventricular-vascular interaction with the potential for noninvasive determination of left ventricular contractility. Circ J. 2009; 73(9):1698-704.
DOI: 10.1253/circj.cj-08-0954.
View
18.
Tartiere J, Tabet J, Logeart D, Tartiere-Kesri L, Beauvais F, Chavelas C
. Noninvasively determined radial dP/dt is a predictor of mortality in patients with heart failure. Am Heart J. 2008; 155(4):758-63.
DOI: 10.1016/j.ahj.2007.11.030.
View
19.
Galie N, Olschewski H, Oudiz R, Torres F, Frost A, Ghofrani H
. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008; 117(23):3010-9.
DOI: 10.1161/CIRCULATIONAHA.107.742510.
View
20.
Oudiz R, Brundage B, Galie N, Ghofrani H, Simonneau G, Botros F
. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. J Am Coll Cardiol. 2012; 60(8):768-74.
DOI: 10.1016/j.jacc.2012.05.004.
View